Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease
Innovating the Future of Alzheimer’s Care at the center of Diagnosis
The ALZpath difference
ALZpath provides diagnostic tools and expertise in Alzheimer’s disease. We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.
Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification
A timely and accessible diagnosis
Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:
- Simple
- Accessible
- Timely
- Cost-effective
- Less invasive
pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
March 25, 2025
ALZpath appoints Samantha Budd Haeberlein, PhD, to its Board of Directors and the expanded advisory role of Henrik Zetterberg, MD, PhD, who will now serve as Distinguished Science Advisor. They join a multidisciplinary group of scientific and industry leaders on ALZpath’s Board and Advisory Board.
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
March 18, 2025
ALZpath has been recognized by Fast Company as one of the World’s Most Innovative Companies of 2025. This honor highlights ALZpath’s impact in advancing accessible, accurate, and early Alzheimer’s diagnostics through its pTau217 blood-based assay, which is integrated into leading diagnostic platforms worldwide.
ALZpath Appoints Mike Banville as CEO
Jan 27, 2025
ALZpath, Inc. has appointed Mike Banville as CEO, effective January 1. Banville brings extensive leadership experience in scaling early-stage companies across healthcare, technology, and education sectors. He aims to drive ALZpath’s mission of advancing accessible, early, and accurate Alzheimer’s diagnosis through its groundbreaking pTau217 blood-based assay.
Bio-Techne and ALZpath Announce Strategic Partnership to Advance Neurodegenerative Disease Research
Nov 18, 2024
Bio-Techne and ALZpath have partnered to accelerate Alzheimer’s research by combining Bio-Techne’s Ella automated immunoassay platform with ALZpath’s pTau217 antibody. The collaboration enables rapid, precise detection of Alzheimer’s biomarkers from plasma samples in just 90 minutes, helping to advance research and treatment development.
